Home » Newsletters » BioWorld Science

BioWorld Science

May 22, 2019

View Archived Issues

Corralling cellular culprits in autism

Universal editing approach to hemophilia A

A new mouse model of the parasitic helminth Loa loa

Umeclidinium is effective and well tolerated in phase II asthma trial

Phase IIa data presented for ANB-020 in patients with peanut allergy

RPRML acts as tumor suppressor and is a potential new biomarker in gastric cancer

Celgene presents results from phase I APHRODITE study of CC-11050

EXOSC5 as a novel prognostic marker in gastric cancer

Plaque transcriptomic analysis provides insights into Peyronie's disease

New treatment approach developed for allergic asthma

L-MIND study of tafasitamab and lenalidomide in DLBCL meets primary endpoint

MicroRNA 597-5p involved in invasion and metastasis in gastric cancer

FDA clears Abeona's IND for phase I/II study of gene therapy ABO-202 for CLN1 disease

Phase III BEACON CRC study of Braftovi triplet therapy meets primary endpoints

Santhera, University of Basel to work together on gene therapy research for LAMA2 MD

Crinetics begins phase I study of CRN-01941 for neuroendocrine tumors

Allergy Therapeutics reports topline results from phase I study of Acarovac MPL

ABI-009, an mTOR inhibitor, shows promise for treating PAH

JCR initiates phase I trial of long-acting growth hormone JR-142

Valneva reports new data from ongoing phase I study of chikungunya vaccine candidate VLA-1553

Bayer presents compounds for cardiovascular diseases

Toray Industries divulges RORC antagonists

Medshine Discovery synthesizes new Wee1 inhibitors

Novartis describes new KCNH2 activators

Debiopharm initiates exploratory study of Debio-1143 with nivolumab in advanced solid tumors

Oncostellae presents androgen and glucocorticoid receptor antagonists

IMDB recommends continuation of phase III trial of Toca-511/Toca-FC in high-grade glioma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...